Manish A Shah1,2, Yoon-Koo Kang3, Peter C Thuss-Patience4, Atsushi Ohtsu5, Jaffer A Ajani6, Eric Van Cutsem7, Silke Hoersch8, Marie-Laurence Harle-Yge9, Sanne Lysbet de Haas10. 1. Division of Hematology and Medical Oncology, Meyer Cancer Center of Weill Cornell Medical College, New York, NY, USA. mas9313@med.cornell.edu. 2. Solid Tumor Service, Gastrointestinal Oncology, Weill Cornell Medicine/New York-Presbyterian Hospital, 1305 York Avenue, New York, NY, 10021, USA. mas9313@med.cornell.edu. 3. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. 4. Department of Hematology, Oncology and Tumor Immunology, Charité - University Medicine Berlin, Berlin, Germany. 5. Department of GI Oncology/Gastroenterology, National Cancer Center Hospital East, Kashiwa, Japan. 6. Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. 7. Digestive Oncology, University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven, Belgium. 8. Statistics Department, KOEHLER eClinical GmbH, Freiburg, Germany. 9. Pharmaceutical Development Clinical Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland. 10. Department of Oncology Biomarker Development, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Abstract
BACKGROUND: Prespecified exploratory biomarker analyses of the phase II/III GATSBY study (NCT01641939) assessed whether patient subgroups experienced a survival benefit from trastuzumab emtansine (T-DM1) versus taxane therapy, and to advance understanding of HER2-positive advanced gastric/gastroesophageal junction cancer (AGC) disease biology. METHODS:Adults with HER2-positive AGC whose disease progressed during/after first-line therapy were enrolled and randomized to receive T-DM1 [Stage 1: 3.6 mg/kg q3w, 2.4 mg/kg qw, or taxane (docetaxel/paclitaxel); Stage 2: 2.4 mg/kg qw or taxane]. Primary efficacy endpoint was overall survival (OS). Prespecified exploratory biomarkers included HER2, HER3, PTEN, PIK3CA mutation status, FcγR, and cMET. Tumor samples from patients who received 2.4 mg/kg T-DM1 (n = 228) or taxane (n = 117) were included. RESULTS:Median OS was longer in subgroups with HER2 immunohistochemistry (IHC) 3+ [9.5 versus 8.3 months for T-DM1 versus taxane; hazard ratio (HR) 0.99 (95% CI 0.68-1.43)] versus HER2 IHC 2+/in situ hybridization-positive [5.2 versus 9.2 months for T-DM1 versus taxane; HR 1.53 (95% CI 0.94-2.50)] tumors. Trends towards increased median OS were also observed in subgroups with > versus ≤ median HER2 mRNA expression, higher versus lower HER2 gene copy number, HER2 gene ratio and H score, and homogenous or nonfocal HER2 IHC staining. T-DM1 was not associated with superior OS versus taxane in any subgroup. CONCLUSIONS: Patients with previously treated HER2-positive AGC with higher HER2 expression experienced a better treatment effect from T-DM1 than those with lower HER2 expression and may derive comparable survival benefits from T-DM1 and taxane therapy. CLINICAL TRIALS REGISTRATION: NCT01641939 ( https://clinicaltrials.gov/ct2/show/NCT01641939 ).
RCT Entities:
BACKGROUND: Prespecified exploratory biomarker analyses of the phase II/III GATSBY study (NCT01641939) assessed whether patient subgroups experienced a survival benefit from trastuzumab emtansine (T-DM1) versus taxane therapy, and to advance understanding of HER2-positive advanced gastric/gastroesophageal junction cancer (AGC) disease biology. METHODS: Adults with HER2-positive AGC whose disease progressed during/after first-line therapy were enrolled and randomized to receive T-DM1 [Stage 1: 3.6 mg/kg q3w, 2.4 mg/kg qw, or taxane (docetaxel/paclitaxel); Stage 2: 2.4 mg/kg qw or taxane]. Primary efficacy endpoint was overall survival (OS). Prespecified exploratory biomarkers included HER2, HER3, PTEN, PIK3CA mutation status, FcγR, and cMET. Tumor samples from patients who received 2.4 mg/kg T-DM1 (n = 228) or taxane (n = 117) were included. RESULTS: Median OS was longer in subgroups with HER2 immunohistochemistry (IHC) 3+ [9.5 versus 8.3 months for T-DM1 versus taxane; hazard ratio (HR) 0.99 (95% CI 0.68-1.43)] versus HER2 IHC 2+/in situ hybridization-positive [5.2 versus 9.2 months for T-DM1 versus taxane; HR 1.53 (95% CI 0.94-2.50)] tumors. Trends towards increased median OS were also observed in subgroups with > versus ≤ median HER2 mRNA expression, higher versus lower HER2 gene copy number, HER2 gene ratio and H score, and homogenous or nonfocal HER2 IHC staining. T-DM1 was not associated with superior OS versus taxane in any subgroup. CONCLUSIONS:Patients with previously treated HER2-positive AGC with higher HER2 expression experienced a better treatment effect from T-DM1 than those with lower HER2 expression and may derive comparable survival benefits from T-DM1 and taxane therapy. CLINICAL TRIALS REGISTRATION: NCT01641939 ( https://clinicaltrials.gov/ct2/show/NCT01641939 ).
Authors: José Baselga; Javier Cortés; Sung-Bae Kim; Seock-Ah Im; Roberto Hegg; Young-Hyuck Im; Laslo Roman; José Luiz Pedrini; Tadeusz Pienkowski; Adam Knott; Emma Clark; Mark C Benyunes; Graham Ross; Sandra M Swain Journal: N Engl J Med Date: 2011-12-07 Impact factor: 91.245
Authors: Steven J Isakoff; Jeffrey A Engelman; Hanna Y Irie; Ji Luo; Saskia M Brachmann; Rachel V Pearline; Lewis C Cantley; Joan S Brugge Journal: Cancer Res Date: 2005-12-01 Impact factor: 12.701
Authors: Sunil Verma; David Miles; Luca Gianni; Ian E Krop; Manfred Welslau; José Baselga; Mark Pegram; Do-Youn Oh; Véronique Diéras; Ellie Guardino; Liang Fang; Michael W Lu; Steven Olsen; Kim Blackwell Journal: N Engl J Med Date: 2012-10-01 Impact factor: 91.245
Authors: José Baselga; Javier Cortés; Seock-Ah Im; Emma Clark; Graham Ross; Astrid Kiermaier; Sandra M Swain Journal: J Clin Oncol Date: 2014-10-20 Impact factor: 44.544
Authors: Ian E Krop; Sung-Bae Kim; Antonio González-Martín; Patricia M LoRusso; Jean-Marc Ferrero; Melanie Smitt; Ron Yu; Abraham C F Leung; Hans Wildiers Journal: Lancet Oncol Date: 2014-05-02 Impact factor: 41.316
Authors: Michael F Press; Catherine E Ellis; Robert C Gagnon; Tobias J Grob; Marc Buyse; Ivonne Villalobos; Zhiyong Liang; Shafei Wu; Yung-Jue Bang; Shu-Kui Qin; Hyun Cheol Chung; Jianming Xu; Joon Oh Park; Krzysztof Jeziorski; Karen Afenjar; Yanling Ma; Monica C Estrada; Douglas M Robinson; Stefan J Scherer; Guido Sauter; J Randolph Hecht; Dennis J Slamon Journal: Mol Cancer Ther Date: 2016-11-03 Impact factor: 6.009
Authors: Zhengyan Yang; Liang Guo; Dan Liu; Limin Sun; Hongyu Chen; Que Deng; Yanjun Liu; Ming Yu; Yuanfang Ma; Ning Guo; Ming Shi Journal: Oncotarget Date: 2015-03-10
Authors: Charlotte I Stroes; Sandor Schokker; Aafke Creemers; Remco J Molenaar; Maarten C C M Hulshof; Stephanie O van der Woude; Roel J Bennink; Ron A A Mathôt; Kausilia K Krishnadath; Cornelis J A Punt; Rob H A Verhoeven; Martijn G H van Oijen; Geert-Jan Creemers; Grard A P Nieuwenhuijzen; Maurice J C van der Sangen; Laurens V Beerepoot; Joos Heisterkamp; Maartje Los; Marije Slingerland; Annemieke Cats; Geke A P Hospers; Maarten F Bijlsma; Mark I van Berge Henegouwen; Sybren L Meijer; Hanneke W M van Laarhoven Journal: J Clin Oncol Date: 2019-12-06 Impact factor: 44.544
Authors: Marcel Mayer; Lisa Nachtsheim; Franziska Hoffmann; Ferdinand von Eggeling; Orlando Guntinas-Lichius; Johanna Prinz; Jens Peter Klußmann; Alexander Quaas; Christoph Arolt; Philipp Wolber Journal: Int J Mol Sci Date: 2022-08-12 Impact factor: 6.208